why choose us

First received: November 11, 2024

Clinical Trial: Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Random Allocation

Study Type: INTERVENTIONAL


Official Title: A Pivotal, Randomized, Single-dose, Open-label, Four-Way Crossover, BE Study of TAH3311 (Apixaban ODF) Under Fasted and Fed Conditions vs. ELIQUIS® Oral Tablet Under Fasted Condition in Healthy Volunt

Brief Summary: This single-dose, open-label, randomized, four-way crossover study evaluates the pharmacokinetics, safety, and tolerability of TAH3311 5 mg in healthy volunteers under fasted and fed conditions.

Read more